The Role of ADRB2 in Myasthenia: Genetic and Immunological Factors

To examine the possibility of using ADRB2 adrenergic receptor agonists for correction of myasthenia-induced immunological and motor disturbances, a method of anti-ADRB2 antibody assay by ELISA was developed. The haplotype of ADRB2 gene was determined by MLPA-PCR in 34 myasthenia patients; blood sera...

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of experimental biology and medicine 2013, Vol.154 (3), p.351-353
Main Authors: Lantsova, V. B., Gerasimov, A. S., Sepp, E. K.
Format: Article
Language:English
Subjects:
Adolescent
Adrenergic Agonists - therapeutic use
Adrenergic receptors
Adult
Antigen-antibody reactions
Autoantibodies
Autoantibodies - blood
Biological products
Biomedical and Life Sciences
Biomedicine
Cell Biology
Child
Enzyme-linked immunosorbent assay
Genetic engineering
Genetic research
Genetically modified organisms
Genetics
Genotype
Glycine
Humans
Internal Medicine
Laboratory Medicine
Middle Aged
Mutation
Myasthenia Gravis - genetics
Myasthenia Gravis - immunology
Pathology
Receptors, Adrenergic, beta-2 - genetics
Receptors, Adrenergic, beta-2 - immunology
Severity of Illness Index
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To examine the possibility of using ADRB2 adrenergic receptor agonists for correction of myasthenia-induced immunological and motor disturbances, a method of anti-ADRB2 antibody assay by ELISA was developed. The haplotype of ADRB2 gene was determined by MLPA-PCR in 34 myasthenia patients; blood sera from 40 patients were examined. The content of antibodies against ADRB2 receptors was elevated in 12 of 30 patients with generalized form of myasthenia. Arg-Arg in position 16 in ADRB2 receptors determines the developmental risk of side effects, while Gly-Gly in the same codon determines tolerance to β 2 -adrenoceptor agonists and is associated with more severe course of myasthenia and resistance to β 2 -adrenoceptor agonists treatment with ADRB2 agonists. The study demonstrated the possibility of using ADRB2 obtained gene engineering technique for quantitatively assay the autoantibodies.
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-013-1948-0